Evaluation of the Distribution and Antimicrobial Susceptibility of Gram-negative Bacteria Isolated from Blood Cultures in Heamatologic Febrile Neutropenia Attacks

Year 2022, Volume: 75 Issue: 3, 373 - 378, 18.10.2022

Güle Çınar

Abstract

Objectives: Bacterial bloodstream infections with resistant pathogens in patients with hematological malignancies are increasing due to the more
use of new chemotherapeutic agents and prophylactic antibiotics. In this study, it was aimed to determine the epidemiology and resistance rates of
gram-negative bacterial pathogens isolated from blood cultures of febrile neutropenic patients with hematological malignancies in order to help
the correct administration of empirical antibiotics and to limit resistance.
Materials and Methods: Antibiotic susceptibility of gram-negative bacteria, which were grown in the blood cultures of hematological febrile
neutropenic patients in a tertiary university hospital between 2019 and 2021 and determined as bloodstream infection, was retrospectively
investigated.
Results: Between January 1, 2019 and December 31, 2021, a total of 388 gram-negative isolates, which were isolated from blood cultures and
evaluated as bloodstream infection, in the febrile neutropenia attacks of patients with hematological malignancies hospitalized in the hematology
service were evaluated, and the most common isolated pathogen was found to be Klebsiella spp. (41.7%). When evaluated in terms of multi-drug
resistance, it was determined that Klebsiella spp. was in the first and Acinetobacter spp. was in the second place. When evaluated in terms of
piperacillin-tazobactam susceptibility, which we frequently use in the empirical treatment of febrile neutropenic patients, 70.3% of Klebsiella
spp., 37.7% of Escherichia coli, 86% of Acinetobacter spp. and 67.5% of Pseudomonas spp. were found to be resistant to piperacillin-tazobactam.
Carbapenem resistance was also found to be between 29% and 80%.
Conclusion: It is noteworthy that all gram-negative strains were highly resistant to piperacillin-tazobactam, which is used as empirical treatment
of febrile neutropenia attacks, and that carbapenem resistance was found at a substantial rate. Considering these data may contribute to reducing
morbidity and mortality while arranging empirical treatment guidelines and antibiotic management programs in febrile neutropenia attacks seen
in hematological malignancy patients both in our hospital and in Turkey.

Keywords

Febrile Neutropenia , Hematologic Malignancy , Antimicrobial Sensitivity , Multidrug Resistance

Project Number

-

Hematolojik Febril Nötropeni Ataklarında Kan Kültürlerinden İzole Edilen Gram-negatif Bakterilerin Dağılımı ve Antimikrobiyal Duyarlılıklarının Değerlendirilmesi

Abstract

Amaç: Hematolojik maligniteleri olan hastalarda dirençli patojenler nedeniyle gelişen bakteriyel kan dolaşımı enfeksiyonları, yeni kemoterapötik
ajanların ve profilaktik antibiyotiklerin daha çok kullanılması nedeniyle artmaktadır. Bu çalışmada, ampirik antibiyotiklerin doğru uygulanmasına
yardımcı olmak ve direnci sınırlamak için hematolojik malignitesi olan febril nötropenik hastalarda kan kültürlerinde üreyen gram-negatif bakteriyel
patojenlerin epidemiyolojisini ve direnç oranlarını belirlemek amaçlanmıştır.

Gereç ve Yöntem: Üçüncü basamak bir üniversite hastanesinde 2019-2021 yıllarında hematolojik febril nötropenik hastaların kan kültürlerinde
üreyen ve kan dolaşımı enfeksiyonu olarak belirlenen gram-negatif bakterilerin antibiyotik duyarlılıkları retrospektif olarak incelendi.

Bulgular: 1 Ocak 2019 ile 31 Aralık 2021 tarihleri arasında hematoloji servisinde yatan hematolojik malignitesi olan hastaların febril nötropeni
ataklarında kan kültürlerinden izole edilen ve kan dolaşımı enfeksiyonu olarak değerlendirilen toplam 388 gram-negatif izolat değerlendirmeye alındı,
en sık izole edilen patojenin Klebsiella spp. (%41,7) olduğu görüldü. Çoklu ilaca direnç açısından değerlendirildiğinde Klebsiella spp.’nin ilk sırada,
Acinetobacter spp.’nin ikinci sırada olduğu belirlendi. Febril nötropenik hastaların ampirik tedavisinde sıklıkla kullandığımız piperasilin-tazobaktam
duyarlılığı açısından değerlendirildiğinde, Klebsiella spp.’nin %70,3, Escherichia coli’nin %37,7, Acinetobacter spp.’nin %86 ve Pseudomonas spp.’nin
%67,5 oranında dirençli olduğu saptandı. Karbapenem direncinin de %29 ila %80 arasında olduğu görüldü.

Sonuç: Febril nötropeni ataklarının ampirik tedavisinde kullanılan piperasilin-tazobaktama tüm gram-negatif suşların yüksek oranda dirençli çıkması
ve karbapenem direncinin de azımsanmayacak oranda bulunması dikkat çekicidir. Hem hastanemizde hem de ülkemizde hematolojik maligniteli
hastalarda görülen febril nötropeni ataklarında ampirik tedavi kılavuzları ve antibiyotik yönetim programları düzenlenirken, bu verilerin göz önünde
bulundurulması morbidite ve mortaliteyi azaltmaya katkıda bulunabilir.

Keywords

Febril Nötropeni , Hematolojik Malignite , Antimikrobiyal Duyarlılık , Çoklu İlaca Direnç

Ethical Statement

Laboratuvar çalışması olduğu ve hasta bilgisi içermediği için etik kurul izni gerekmemektedir.

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1. Villafuerte-Gutierrez P, Villalon L, Losa JE, et al. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. Adv Hematol. 2014;2014:986938 Erratum in: Adv Hematol 2019;2019.
• 2. Kokkayil P, Agarwal R, Mohapatra S, et al. Bacterial profile and antibiogram of blood stream infections in febrile neutropenic patients with haematological malignancies. J Infect Dev Ctries. 2018;12:442-447. https:// doi.org/10.3855/jidc.9725.
• 3. Gedik H, Simşek F, Kantürk A, et al. Bloodstream infections in patients with hematological malignancies: which is more fatal—cancer or resistant pathogens? Ther Clin Risk Manag. 2014;10:743-752.
• 4. Blennow O, Ljungman P. The challenge of antibiotic resistance in haematology patients. Br J Haematol. 2016;172:497-511.
• 5. Garcia-Vidal C, Cardozo-Espinola C, Puerta-Alcalde P, et al. Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. PLoS One. 2018;13:e0199531.
• 6. Tang Y, Wu X, Cheng Q, et al. Inappropriate initial antimicrobial therapy for hematological malignancies patients with gram-negative bloodstream infections. Infection. 2020;48:109-116.
• 7. Righi E, Peri AM, Harris PN, et al. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72:668-677.
• 8. Fentie A, Wondimeneh Y, Balcha A, et al. Bacterial profile, antibiotic resistance pattern and associated factors among cancer patients at University of Gondar Hospital, Northwest Ethiopia. Infect Drug Resist. 2018;11:2169-2178.
• 9. Rolston KV. Challenges in the treatment of infections caused by grampositive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis. 2005;40(Suppl 4):S246.
• 10. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011; 52:e56.
• 11. Moghnieh R, Kanafani ZA, Abi Hanna P, et al. 2016 Lebanese Society of Infectious Diseases and Clinical Microbiol- ogy guidelines on the management of febrile neutropenia in adult cancer patients in the era of growing antimicrobial resistance. Lebanese Medical Journal. 2017;103:1-20.
• 12. Diekema DJ, Hsueh P-R, Mendes RE, Pfaller MA, Rolston KV, Sader HS, et al. The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother. 2019;63:e00355-19.
• 13. The European Committee on Antimicrobial Susceptibility Testing (EUCAST), 2019. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 1 Jan - 31 Dec, 2019
• 14. The European Committee on Antimicrobial Susceptibility Testing (EUCAST), 2020. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 1 Jan - 31 Dec, 2020
• 15. The European Committee on Antimicrobial Susceptibility Testing (EUCAST), 2021. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, 1 Jan - 31 Dec, 2021
• 16. Vasoo S, Cunningham SA, Kohner PC, et al. Comparison of a novel, rapid chromogenic biochemical assay, the carba NP test, with the modified Hodge test for detection of carbapenemase-producing gram-negative bacilli. J Clin Microbiol. 2013;51:3097-3101.
• 17. Gupta A, Singh M, Singh H, et al. Infections in acute myeloid leukemia: An analysis of 382 febrile episodes. Med Oncol. 2010;27:1037 45.
• 18. Hamidi AA, Başaran S, Çağatay AA, et al. Febril Nötropenik Hastalarda Bakteriyemi Etkeni Olabilecek Patojenler, Direnç Durumu ve Hastaların Özellikleri Klimik Dergisi. 2009;22:88-91.
• 19. Demirkaya MH, Yeşilkaya A, Akcil-Ok M, et al. İmmunokompromize Hastalarda Bakteriyemi Etkenleri. Klimik Dergisi. 2017;30: 32-35.
• 20. Çam B ve Ulu Kılıç A. Erişkin Hematoloji ve Kemik İliği Transplantasyonu (KİT) Ünitelerinde Yatan Hematolojik Maligniteli Hastalarda Gelişen Kan Dolaşımı Enfeksiyonlarının İncelenmesi. Kırşehir Ahi Evran Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi. 2020;1:158-169.
• 21. Gafter-Gvili A, Fraser A, Paul M, et al. Cochrane gynaecological, neurooncology and orphan cancer group. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386.
• 22. Mikulska M, Averbuch D, Tissot F, et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect. 2018;76:20-37.
• 23. Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guide-line update. J Clin Oncol. 2018;36:1443-1453.
• 24. Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenemresistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58:1274-1283.
• 25. Micozzi A, Gentile G, Minotti C, et al. Carbapenem-resistant Klebsiella pneumoniae in high-risk hematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias. BMC Infect Dis. 2017;17:203.